title: Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis.
abstract: In our previous studies, we have shown that patients with serous ovarian carcinoma in advanced surgical stage disease have a particularly poor prognosis if they carry the HLA-A*02 genotype. This represent a stronger prognostic factor than loss or downregulation of the MHC class I heavy chain (HC) on tumor cells. In this study, we investigated the expression of the non-classical, immune tolerogenic HLA -G and -E on the tumor cells along with the infiltration of immune cells in the tumor microenvironment. FFPE primary tumors from 72 patients with advanced stages of serous adenocarcinoma and metastatic cells present in ascites fluid from 8 additional patients were included in this study. Both expression of HLA-G and aberrant expression of HLA-E were correlated to a significant worse prognosis in patients with HLA-A*02, but not with different HLA genotypes. Focal cell expression of HLA-G correlated to a site-specific downregulation of classical MHC class I HC products and aberrant HLA-E expression, showing a poor survival. HLA-G was more frequently expressed in metastatic cells than in primary tumor lesions and the expression of HLA-G inversely correlated with the frequency of tumor infiltrating immune cells. All these parameters can contribute together to identify and discriminate subpopulations of patients with extremely poor prognosis and can give them the opportunity to receive, and benefit of individually tailored treatments.
authors.affiliation: Department Oncology-Pathology; Karolinska Institutet; Karolinska University Hospital ; Stockholm, Sweden.
authors.forename: Emilia
authors.initials: E
authors.lastname: Andersson
authors.affiliation: Department Oncology-Pathology; Karolinska Institutet; Karolinska University Hospital; Stockholm, Sweden; Division of Molecular Oncology of Gastrointestinal Tumors; German Cancer Research Center; Heidelberg, Germany.
authors.forename: Isabel
authors.initials: I
authors.lastname: Poschke
authors.affiliation: Department Oncology-Pathology; Karolinska Institutet; Karolinska University Hospital ; Stockholm, Sweden.
authors.forename: Lisa
authors.initials: L
authors.lastname: Villabona
authors.affiliation: Department Oncology-Pathology; Karolinska Institutet; Karolinska University Hospital ; Stockholm, Sweden.
authors.forename: Joseph W
authors.initials: JW
authors.lastname: Carlson
authors.affiliation: Department Oncology-Pathology; Karolinska Institutet; Karolinska University Hospital ; Stockholm, Sweden.
authors.forename: Andreas
authors.initials: A
authors.lastname: Lundqvist
authors.affiliation: Department Oncology-Pathology; Karolinska Institutet; Karolinska University Hospital ; Stockholm, Sweden.
authors.forename: Rolf
authors.initials: R
authors.lastname: Kiessling
authors.affiliation: Institute of Medical Immunology; Martin Luther University Halle-Wittenberg ; Halle/Saale, Germany.
authors.forename: Barbara
authors.initials: B
authors.lastname: Seliger
authors.affiliation: Department Oncology-Pathology; Karolinska Institutet; Karolinska University Hospital ; Stockholm, Sweden.
authors.forename: Giuseppe V
authors.initials: GV
authors.lastname: Masucci
keywords: HLA-A*02; HLA-E; HLA-G; immunohistochemistry; ovarian cancer; prognosis; serous adenocarcinoma